The Protocol Review Committee (PRC) of University of Pittsburgh Cancer Institute (UPCI) is responsible for reviewing all clinical cancer research studies conducted at the University of Pittsburgh and UPMC prior to initiation of the study. Its activities are overseen by the Clinical Research Oversight Committee (CROC) along with two other entities that work in parallel to orchestrate cancer clinical research, the Data Safety and Monitoring Committee (DSMC) and the Clinical Research Services (CRS). The PRC also works in conjunction with three other parts of the clinical trials enterprise, the University of Pittsburgh IRB, the UPCI Biostatistics Facility, and the disease-oriented management teams, to promote the highest scientific quality and most efficient conduct of cancer clinical trials at the UPCI. The PRC is comprised of three committees. Committees A and B each meet once a month in order to facilitate prompt review of cancer treatment protocols. Committee C is responsible for reviewing all behavioral, cancer epidemiology, cancer prevention and control, and complementary medicine protocols as the need arises. The PRC evaluates each protocol to ensure appropriate study design and scientific quality and availability of patient and fiscal resources required for successful completion of the trial proposed. Membership of the PRC includes a diverse group of cancer experts including hematology/oncology, surgical oncology, urologic oncology, pharmacology, biostatistics, nursing, regulatory affairs, and laboratory scientists. PRC approval of cancer clinical trials is required before the study can be submitted to the University of Pittsburgh IRB. All UPCI trials are reviewed for accrual every six months. Studies achieving less than 30% of target accrual are flagged for review. A notification letter is sent to the PI requesting a plan to increase accrual, and the study is re-reviewed for accrual in six months. To simplify documentation and monitoring of UPCI clinical trials activities, all formal committees (PRC, CROC and three DSMC) have a single recording secretary, who is responsible for recording the minutes of each meeting, and facilitates communication between the committees, University and UPMC regulatory committees, regulatory agencies, and UPCI Pis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382695
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$125,600
Indirect Cost
$78,573
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Toptan, Tuna; Abere, Bizunesh; Nalesnik, Michael A et al. (2018) Circular DNA tumor viruses make circular RNAs. Proc Natl Acad Sci U S A 115:E8737-E8745

Showing the most recent 10 out of 1187 publications